Akutpsychiatrie für Menschen mit Intelligenzminderung und psychischen Störungen

Zusammenfassung

Der Beitrag analysiert die komplexen klinischen, pharmakologischen und milieutherapeutischen Anforderungen an die Behandlung von Menschen mit Intelligenzminderung (IM) und komorbiden psychischen Störungen anhand zweier Fallberichte der spezialisierten heilpädagogischen Station H des Bezirkskrankenhauses Bayreuth.

• Literatur

• 1 Maulik PK, Mascarenhas MN, Mathers CD. et al. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil 2011; 32: 419-436
• 2 Brugha TS, McManus S, Bankart J. et al. Epidemiology of autism spectrum disorders in adults in the community in England. Arch Gen Psychiatry 2011; 68: 459-465
• 3 Dunn K, Rydzewska E, MacIntyre C. et al. The prevalence and general health status of people with intellectual disabilities and autism co-occurring together: a total population study. J Intellect Disabil Res 2019; 63: 277-285
• 4 Buckles J, Luckasson R, Keefe E. A systematic review of the prevalence of psychiatric disorders in adults with intellectual disability, 2003–2010. J Ment Health Res Intellect Disabil 2013; 6: 181-207
• 5 Koslowski N, Klein K, Arnold K. et al. Effectiveness of interventions for adults with mild to moderate intellectual disabilities and mental health problems: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 469-474
• 6 Bigby C. Social inclusion and people with intellectual disability and challenging behaviour: a systematic review. J Intellect Dev Disabil 2012; 37: 360-374
• 7 Pinals DA, Hovermale L, Mauch D. et al. Persons with intellectual and developmental disabilities in the mental health system: part 1. Clinical considerations. Psychiatr Serv 2022; 73: 313-320
• 8 Wellkamp R, de Cruppé W, Schwalen S. et al. Menschen mit geistiger Behinderung (MmgB) in der ambulanten medizinischen Versorgung: Barrieren beim Zugang und im Untersuchungsablauf. Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz 2023; 66: 184-198
• 9 Moss S, Emerson E, Kiernan C. et al. Psychiatric symptoms in adults with learning disability and challenging behaviour. Br J Psychiatry 2000; 177: 452-456
• 10 Martin P. Medical treatment for people with intellectual impairment. Dtsch Arztebl Int 2019; 116: 807-808
• 11 Glover G, Bernard S, Branford D. et al. Use of medication for challenging behaviour in people with intellectual disability. Br J Psychiatry 2014; 205: 6-7
• 12 McDermott S, Durkin MS, Schupf N. et al. Epidemiology and etiology of mental retardation. In Jacobson JW, Mulick JA, Rojahn J. editors. Handbook of intellectual and developmental disabilities. Boston, MA: Springer US; 2007: 3-40
• 13 Plomin R. Commentary: the origins of intellectual disability. J Child Psychol Psychiatry 2022; 63: 1103-1105
• 14 Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme 10. Revision German Modification Version 2025. 2025 Zugriff am 31. Juli 2025 unter: https://klassifikationen.bfarm.de/icd-10-gm/kode-suche/htmlgm2025/index.htm
• 15 Schützwohl M, Sappok T. Psychische Gesundheit bei Personen mit Intelligenzminderung. Nervenarzt 2020; 91: 271-281
• 16 Mazza MG, Rossetti A, Crespi G. et al. Prevalence of co-occurring psychiatric disorders in adults and adolescents with intellectual disability: a systematic review and meta-analysis. J Appl Res Intellect Disabil 2020; 33: 126-138
• 17 Morgan VA, Leonard H, Bourke J. et al. Intellectual disability co-occurring with schizophrenia and other psychiatric illness: population-based study. British Journal of Psychiatry 2008; 193 (5) 364-372
• 18 Cooper SA, Smiley E. Prevalence of intellectual disabilities and epidemiology of mental ill-health in adults with intellectual disabilities. 2nd edn. Oxford: Oxford University Press;
• 19 Deb S, Thomas M, Bright C. Mental disorders in adults with intellectual disability: 2. The rate of behaviour disorder among a community-based population aged between 16–64 years. J Intellect Disabil Res 2001; 45: 506-514
• 20 Davies LE, Oliver C. The purported association between depression, aggression, and self-injury in people with intellectual disability: a critical review of the literature. Am J Intellect Dev Disabil 2014; 119: 452-457
• 21 Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord 03/2011; 3 (1) 57-67
• 22 Mefford HC, Batshaw ML, Hoffman EP. Genomics, intellectual disability, and autism. N Engl J Med 23.02.2012; 366 (8) 733-43
• 23 Strydom A, Hassiotis A, King M. et al. The relationship of dementia prevalence in older adults with intellectual disability (ID) to age and severity of ID. Psychol Med 01/2009; 39 (1) 13-21
• 24 Simonoff E, Pine DS. et al. Intellectual disability. In Rutter’s Child and Adolescent Psychiatry. Chichester: John Wiley & Sons; 2015: 719-737
• 25 Robertson J, Hatton C, Emerson E. et al. Prevalence of epilepsy among people with intellectual disabilities: A systematic review. Seizure 08/2015; 29: 46-62
• 26 Weih M, Köhler S, Schöll N. et al. Mental, neurological, and somatic comorbidities and their treatment in persons with intellectual disability. Dtsch Arztebl Int 2022; 119: 418-414
• 27 Bruinsma E, van den Hoofdakker BJ, Groenman AP. et al. Non-pharmacological interventions for challenging behaviours of adults with intellectual disabilities: a meta-analysis. J Intellect Disabil Res 2020; 64: 561-578
• 28 Lee AH, DiGiuseppe R. Anger and aggression treatments: a review of meta-analyses. Curr Opin Psychol 2018; 19: 65-74
• 29 Didden R, Duker PC, Korzilius H. Meta-analytic study on treatment effectiveness for problem behaviors with individuals who have mental retardation. Am J Ment Retard 1997; 101: 387-399
• 30 Bundesministerium der Justiz. Bürgerliches Gesetzbuch (BGB). 2025 Zugriff am 31. Juli 2025 unter: https://www.gesetze-im-internet.de/bgb/
• 31 Zúñiga Mouret R, Greenbaum JP, Doll HM. et al. The adaptor protein 2 (AP2) complex modulates habituation and behavioral selection across multiple pathways and time windows. iScience 2024; 27: 109455
• 32 Chinoy A, Nicholson J, Skae M. et al. Neurodevelopmental abnormalities in patients with familial hypocalciuric hypercalcemia type 3. J Pediatr 2023; 257: 113367
• 33 Stevenson M, Bayliss AL, Stokes VJ. et al. Adaptor protein 2 sigma subunit (AP2S1) variants associated with neurodevelopmental disorders. medRxiv 2024 Verfügbar unter: Zugriff am 31. Juli 2025 unter: http://medrxiv.org/lookup/doi/10.1101/2024.07.22.24310683
• 34 Aashiq M, Malallah AJ, Khan F. et al. Clinical and biochemical features in a case of familial hypocalciuric hypercalcemia type 3 with AP2S1 gene mutation in codon Arg15His. Case Rep Pediatr 2020; 2020: 7312894
• 35 Tsiouris JA. Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment?. J Intellect Disabil Res 2010; 54: 1-16
• 36 Matson JL, Wilkins J. Antipsychotic drugs for aggression in intellectual disability. Lancet 2008; 371: 9-10
• 37 Lunsky Y, Khuu W, Tadrous M. et al. Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities. Can J Psychiatry 2018; 63: 361-369
• 38 Frogley C, Taylor D, Dickens G. et al. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol 2012; 15: 1351-1371
• 39 Andreea T, Petru I, Miron AA. et al. Clozapine for treatment-refractory aggressive behavior. Psychiatr Q 2021; 92: 721-733
• 40 De Deyn PP, Buitelaar J. Risperidone in the management of agitation and aggression associated with psychiatric disorders. Eur Psychiatry 2006; 21: 21-28
• 41 Bak M, Weltens I, Bervoets C. et al. The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis. Eur Psychiatry 2019; 57: 78-100
• 42 Komenda-Schned S, Moritz PC, Zeilinger Dr EL. Rezension von Skala der emotionalen Entwicklung – Diagnostik 2 (SEED-2). Z Klin Psychol Psychother 2024; 53: 149-154
• 43 Vereinte Nationen (United Nations). Convention on the Rights of Persons with Disabilities (CRPD). 2006 Zugriff am 31. Juli 2025 unter: https://documents.un.org/doc/undoc/gen/n06/500/79/pdf/n0650079.pdf?OpenElement
• 44 Wolfmayr F. Mein neues Auto macht mir viel Freude – In Norwegen ist Leben mit Behinderung normal. Z Menschen Anderswo 2024 6
• 45 Deutscher Bundestag. Ausschuss für Arbeit und Soziales besucht Norwegen und Schweden. Berlin: Deutscher Bundestag; 09.06.2022. Zugriff am 31. Juli 2025 unter: https://www.bundestag.de/webarchiv/presse/pressemitteilungen/2022/pm-220609-delegationsreise-afarbsoz-norwegen-schweden-898842